These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37031619)

  • 1. Dose-sparing effect of Sabin-derived inactivated polio vaccine produced in Japan by intradermal injection device for rats.
    Itoh E; Shimizu S; Ami Y; Iwase Y; Someya Y
    Biologicals; 2023 May; 82():101677. PubMed ID: 37031619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
    Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.
    Anand A; Molodecky NA; Pallansch MA; Sutter RW
    Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
    Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
    Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
    Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
    Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.
    Troy SB; Kouiavskaia D; Siik J; Kochba E; Beydoun H; Mirochnitchenko O; Levin Y; Khardori N; Chumakov K; Maldonado Y
    J Infect Dis; 2015 Jun; 211(12):1969-76. PubMed ID: 25567841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba.
    Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Garcia G; Hung LH; Martinez Y; Sutter R
    Vaccine; 2015 Jan; 33(2):307-13. PubMed ID: 25448109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
    Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
    Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
    J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
    Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).
    Li Z; Ding W; Guo Q; Liu Z; Zhu Z; Song S; Li W; Liao G
    Hum Vaccin Immunother; 2018; 14(8):1987-1994. PubMed ID: 29601259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
    Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
    Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.
    Donadei A; Kraan H; Ophorst O; Flynn O; O'Mahony C; Soema PC; Moore AC
    J Control Release; 2019 Oct; 311-312():96-103. PubMed ID: 31484041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.
    Wang Y; Zade J; Moon SS; Weldon W; Pisal SS; Glass RI; Dhere RM; Jiang B
    Vaccine; 2019 Jan; 37(5):698-704. PubMed ID: 30626530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
    Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
    Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan.
    Satoh H; Tanaka-Taya K; Shimizu H; Goto A; Tanaka S; Nakano T; Hotta C; Okazaki T; Itamochi M; Ito M; Okamoto-Nakagawa R; Yamashita Y; Arai S; Okuno H; Morino S; Oishi K
    Vaccine; 2019 Mar; 37(14):1964-1971. PubMed ID: 30827736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.